Two 5-bagger health tech ASX shares ready to rocket again: expert

These stocks have risen 727% and 456% over the past five years, but one advisor reckons they're about to take off once more.

| More on:
Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There is no getting around the fact that ASX growth shares have performed terribly this year.

However, over the longer term, as the market works its way through entire economic cycles, a business can grow sufficiently to eventually put investors ahead.

Some ASX shares involved in health technology are prime examples. 

Those companies have a foot each in two sectors that have been hammered in 2022. But a long-term perspective might prove fruitful, as is the case with these two stocks:

Long-term growth and short-term defence

Imaging software provider Pro Medicus Limited (ASX: PME) has seen its shares dive 11.5% year to date.

However, over the past five years, its shareholders have been celebrating a remarkable 727% rise in their investments, excluding dividends.

For Medallion Financial Group private client advisor Stuart Bromley, the stock is both a long-term growth story and a short-term defensive holding.

"We believe future growth justifies a relatively high price-earnings ratio," Bromley told The Bull.

"Existing clients are renewing contracts, providing Pro Medicus with defensive, long-term revenues."

In recommending the ASX share as a buy, Bromley noted the 2022 financial year saw underlying revenue increase 38% to $93.5 million.

"This medical imaging technology business is taking impressive market share, primarily at the top end of the big and lucrative US market."

Admittedly other professionals are more lukewarm on Pro Medicus than Bromley. According to CMC Markets, eight out of 13 analysts currently rate the health tech stock as a hold.

New CEO from big pharma

The Polynovo Ltd (ASX: PNV) share price has plunged more than 8% since mid-August.

But, similar to Pro Medicus, it has rewarded investors handsomely over the long term. The ASX share has rocketed up 456% over the past five years.

"The company provides dermal regeneration solutions via its NovoSorb biodegradable polymer technology," said Bromley.

"The company posted unaudited record first quarter sales of $12.5 million in fiscal year 2023."

For Bromley, a big catalyst and endorsement for Polynovo shares came a few months ago.

"We're encouraged that Swami Raote, a former US Johnson & Johnson (NYSE: JNJ) veteran of 30 years, was appointed chief executive in July," he said.

"Raote brings a lot of connections to Polynovo."

The advisor admitted Polynovo has had a long run as a cash-burning business, but he can see the light at the end of the tunnel.

"Breakeven is now closer for this business, with a net loss after tax of just $1.19 million in fiscal year 2022."

Bromley's peers are more convinced about this ASX share, with four out of five analysts currently surveyed on CMC Markets recommending Polynovo as a strong buy.

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended POLYNOVO FPO and Pro Medicus Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Johnson & Johnson. The Motley Fool Australia has positions in and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.
Healthcare Shares

This ASX 200 healthcare share is sinking 9% on CEO exit

Investors are selling off this stock on Tuesday. Here's what you need to know.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why is the CSL share price falling on Monday?

The ASX 200 biotech stock has lost 9% of its value since the start of the new year.

Read more »

Health professional working on his laptop.
Healthcare Shares

Are Sonic Healthcare or CSL shares a better buy?

Which of these healthcare giants is a better buy?

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Dividend Investing

Hoping to bag the boosted dividend from CSL shares? Here's your deadline…

The ASX 200 biotech is rewarding investors with a 9% higher interim dividend this year.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

2 ASX healthcare shares rated as top buys

Are these two names healthy choices for your portfolio? Let's see.

Read more »

A young woman holds her hand to her mouth in surprise as she reads something on her laptop.
Healthcare Shares

Why Mesoblast shares could still be dirt cheap even after 700% gain

This biotech has been on fire but the gains may not be over yet according to Bell Potter.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

The 'crucial' growth metric that makes CSL shares a buy today

A leading expert points to a critical growth metric that could boost CSL shares in 2025.

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Healthcare Shares

Guess which ASX 200 biotech stock is jumping 7% on big news

What is getting investors excited today? Let's find out.

Read more »